Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Active, not recruiting · NCT03463460 · Registry updated 2026-08-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Thymus Neoplasms, lymphatic system disorder, mixed neoplasm, neoplasm, thymoma | Active, not recruiting | Phase 2 | 2026-08-06 | NCT03463460 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dwight Owen | 3 |
| National Cancer Institute (NCI) | 3015 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Indiana University | Indianapolis | United States | 160 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |